We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s Benefit-Risk Framework is Good, but Needs Work, BIO Says
FDA’s Benefit-Risk Framework is Good, but Needs Work, BIO Says
The FDA could further improve the transparency of its benefit-risk assessments in drug regulatory decisions by disclosing more information in complete response letters, BIO suggested in written comments to the agency.